- Home
- SRZN vs IOBT Comparison
SRZN vs IOBT Comparison
Compare SRZN & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- IOBT
- Stock Information
- Founded
- SRZN 2015
- IOBT 2014
- Country
- SRZN United States
- IOBT Denmark
- Employees
- SRZN N/A
- IOBT N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- IOBT Health Care
- Exchange
- SRZN Nasdaq
- IOBT Nasdaq
- Market Cap
- SRZN 85.6M
- IOBT 91.6M
- IPO Year
- SRZN N/A
- IOBT 2021
- Fundamental
- Price
- SRZN $10.06
- IOBT $1.33
- Analyst Decision
- SRZN Strong Buy
- IOBT Strong Buy
- Analyst Count
- SRZN 2
- IOBT 3
- Target Price
- SRZN $38.50
- IOBT $8.67
- AVG Volume (30 Days)
- SRZN 13.7K
- IOBT 5.8M
- Earning Date
- SRZN 08-08-2025
- IOBT 08-26-2025
- Dividend Yield
- SRZN N/A
- IOBT N/A
- EPS Growth
- SRZN N/A
- IOBT N/A
- EPS
- SRZN N/A
- IOBT N/A
- Revenue
- SRZN $12,621,000.00
- IOBT N/A
- Revenue This Year
- SRZN N/A
- IOBT N/A
- Revenue Next Year
- SRZN N/A
- IOBT N/A
- P/E Ratio
- SRZN N/A
- IOBT N/A
- Revenue Growth
- SRZN N/A
- IOBT N/A
- 52 Week Low
- SRZN $5.90
- IOBT $0.66
- 52 Week High
- SRZN $18.17
- IOBT $2.48
- Technical
- Relative Strength Index (RSI)
- SRZN 55.46
- IOBT 38.20
- Support Level
- SRZN $9.03
- IOBT $0.98
- Resistance Level
- SRZN $10.95
- IOBT $2.04
- Average True Range (ATR)
- SRZN 0.99
- IOBT 0.29
- MACD
- SRZN 0.03
- IOBT -0.12
- Stochastic Oscillator
- SRZN 44.88
- IOBT 24.48
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.